Citigroup Inc Eliem Therapeutics, Inc. Transaction History
Citigroup Inc
- $190 Billion
- Q1 2025
A detailed history of Citigroup Inc transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 1,850,118 shares of ELYM stock, worth $7.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,850,118
Previous 22,731
8039.18%
Holding current value
$7.6 Million
Previous $93,000
8075.27%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ELYM
# of Institutions
72Shares Held
53.3MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$129 Million2.09% of portfolio
-
Janus Henderson Group PLC London, X03.18MShares$13.1 Million0.01% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA2.61MShares$10.7 Million3.29% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.5MShares$6.18 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.04MShares$4.27 Million0.19% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $109M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...